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connected to a pseudopeptide functionalized with an 18F isotope
(Fig. 1A) (9, 10).
PSMA, a type II glutamate carboxypeptidase encoded by the
folate hydrolase 1 gene (FOLH1) (11, 12), is expressed primarily in the duodenum, small intestine, nervous system, salivary
gland, and prostate (13). It modulates glutamate signaling induced
by the metabotropic glutamate receptor (mGluR) pathway (14),
cleaving glutamate from both dietary folic acid and the
Signiﬁcance
Glutamate-ureido-lysine (GUL) probes are speciﬁc for
prostate-speciﬁc membrane antigen (PSMA), overexpressed
by most prostate cancers. This antigen can be lost as the
cancer progresses. Recent reports have indicated that GUL
probes can still identify these PSMA-negative tumors, indicating that the expression of alternative PSMA-like proteins
may change during disease progression. In this study we
identiﬁed two such candidate protein targets, NAALADaseL
and mGluR8, by using a combined computational chemistry,
data mining, molecular biology, radiochemistry, and synthetic chemistry approach. This work consequently prepares
the groundwork for developing speciﬁc probes that can
identify this progression, indicates directions for neuroendocrine prostate cancer research, and highlights the utility of a
multidisciplinary approach for the rapid identiﬁcation of
unidentiﬁed proteins interacting with diagnostic probes.

PSMA j prostate cancer j glutamate-ureido-lysine j molecular imaging j
PET
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n 2021, 248,530 American men will be diagnosed with, and
34,130 will die from, prostate cancer. Although mortality has
fallen 52% from its 1993 peak, prostate cancer remains a leading
cause of cancer death (1). The use of positron emission tomography (PET) imaging for accurate diagnosis and localization of
tumors has started to improve prostate cancer staging, enhancing
patient management (2). Prostate-specific membrane antigen
(PSMA), a cell surface protein expressed in the majority of prostate cancers, can be visualized by PET imaging employing radiolabeled antibodies. Next-generation imaging agents based on small
molecule moieties, particularly the PSMA-targeting peptidomimetic glutamate-ureido-lysine (GUL), demonstrate superior
pharmacokinetics (fast tumor uptake and rapid blood clearance) over radiolabeled PSMA antibodies (Fig. 1A) (3). The
molecular mode of action of GUL-based probes, however, is
not completely understood (4, 5). The leading clinical candidates are US Food and Drug Administration (FDA)–approved
68
Ga-PSMA-11 (Ga-GUL) (6), where the GUL head is conjugated
to an acyclic hexadentate gallium ligand, and both 18F-PSMA-1007
(F-GUL) (7) and FDA-approved 18F-DCFPyL (8), where GUL is
PNAS 2022 Vol. 119 No. 4 e2025710119
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Prostate-speciﬁc membrane antigen (PSMA) is highly overexpressed
in most prostate cancers and is clinically visualized using PSMAspeciﬁc probes incorporating glutamate-ureido-lysine (GUL).
PSMA is effectively absent from certain high-mortality, treatment-resistant subsets of prostate cancers, such as neuroendocrine prostate cancer (NEPC); however, GUL-based PSMA tracers
are still reported to have the potential to identify NEPC metastatic tumors. These probes may bind unknown proteins associated with PSMA-suppressed cancers. We have identiﬁed the
up-regulation of PSMA-like aminopeptidase NAALADaseL and the
metabotropic glutamate receptors (mGluRs) in PSMA-suppressed
prostate cancers and ﬁnd that their expression levels inversely correlate with PSMA expression and are associated with GUL-based
radiotracer uptake. Furthermore, we identify that NAALADaseL
and mGluR expression correlates with a unique cell cycle signature. This provides an opportunity for the future study of the biology of NEPC and potential therapeutic directions. Computationally
predicting that GUL-based probes bind well to these targets, we
designed and synthesized a ﬂuorescent PSMA tracer to investigate
these proteins in vitro, where it shows excellent afﬁnity for PSMA,
NAALADaseL, and speciﬁc mGluRs associated with poor prognosis.

BIOPHYSICS AND
COMPUTATIONAL BIOLOGY
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Fig. 1. Structure of clinical PSMA probes and their binding modes within the PSMA, NAALADaseL, and mGluR8 active sites. (A) Structure of Ga-GUL
(Top) and F-GUL (Bottom). (B) F-GUL within the PSMA active site, showing the different regions of the active site and the substructure nomenclature
of the probe. Computational modeling of (C) F-GUL and (D) Ga-GUL within the PSMA active site (2XEG), (E) F-GUL and (F) Ga-GUL within the NAALADaseL active site (4TWE), and (G) F-GUL and (H) Ga-GUL within the mGluR8 active site (6BSZ). The imaging moieties are shown in red (F-GUL) and beige
(Ga-GUL) with the GUL moiety in brown (F-GUL) and purple (Ga-GUL). Key residues which form strong interactions—H bonds (yellow dashed lines) and
π cation (green dashed line)—are highlighted in green, and zinc, chlorine, gallium, and ﬂuorine atoms are spheres colored purple, green, blue, and
orange, respectively.

neurotransmitter
N-acetyl-L-aspartyl-L-glutamate
(NAAG).
PSMA overexpression is a hallmark of prostate cancer including
metastatic castration-resistant prostate adenocarcinoma (15, 16).
Despite this, both immunohistochemical and genomic data have
demonstrated that PSMA is expressed at only very low levels, if
at all, in neuroendocrine prostate cancer (NEPC) (17, 18), an
aggressive form of androgen receptor (AR)–independent prostate cancer with exceedingly high mortality rates (18). While de
novo NEPC is rare, this hard-to-treat phenotype can emerge as a
prostate cancer resistance mechanism to AR-targeted therapies,
shedding the PSMA biomarker concurrent with a down-regulation
of the AR (18–20).
Paschalis et al. (21) reported PSMA expression can be heterogeneous within tumors of a single patient, so GUL-based radiotracers would still delineate PSMA-positive portions of tumors.
2 of 11 j PNAS
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However, if other portions of the tumor or metastatic colonies
were PSMA-negative, these would not be observed. Similarly,
GUL-based radiotracers are not expected to be useful for imaging PSMA-negative prostate tumors such as NEPC. A less specific agent, 18F-fluorodeoxyglucose, which exploits cancer cells’
increased glucose uptake, is often used for NEPC imaging as in
small cell lung cancer (22, 23).
Unexpectedly, Iravani et al. demonstrated that GUL-based
imaging can identify immunohistochemistry-validated PSMAnegative metastatic tumors despite the tumor’s PSMA-negativity
(24). Similarly, another recent study by Derlin et al. showed that
neuroendocrine marker profiles do not reliably predict the outcome of PSMA-targeted radioligand therapy (25). Furthermore,
although PSMA expression is correlated with GUL radioligand
uptake (26), GUL-based PSMA tracers have also resulted in false
Bakht et al.
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F-GUL and Ga-GUL Are Predicted to Have High Affinity for PSMA.

GUL-based probes interact with three components of PSMA’s
active site: the zinc ions, the pharmacophore (S10 ) site, and the
hydrophobic S1 accessory pocket (Fig. 1B) (28). PSMA’s active
site hosts two Zn2+ ions, responsible for substrate cleavage (SI
Appendix, Fig. S1A) (29, 30). The S10 site, which is highly specific for glutamate moieties, determines substrate specificity
(31). The large hydrophobic S1 accessory pocket, hosting the
rest of the substrate, is far more promiscuous allowing for binding of both folate and NAAG (32).
To better understand probe–protein interactions, in silico
docking studies were performed between the two GUL radiolabels and a computationally relaxed PSMA protein (Protein
Data Bank [PDB] ID 2XEG) (33) (Movies S1 and S2).
Although the ligands’ conformations differ (Fig. 1 C and D),
both share similar interactions with the same Tyr552 active site
residue and the Zn2+ ions (SI Appendix, Fig. S1B), but F-GUL
does not extend into the S10 site like Ga-GUL does. Both probes
are predicted to have high affinity for PSMA, with induced-fit
docking scores around 15 kcal/mol (Table 1). Computed binding modes are consistent with the previously hypothesized interactions (31, 34, 35).
The P100 glutamate carboxylate moiety of F-GUL (Fig. 1C)
forms strong interactions with the zincs (2.06 and 1.95 Å) and
a strong hydrogen bond (2.06 Å) to the phenolic H of the S10
Tyr552. A major structural feature of PSMA’s S1 site is the
accessory pocket, whose entrance lid comprises three arginine
residues (Arg536, Arg534, and Arg463) that can flip open to
accommodate larger molecules. The P10 carboxylate of F-GUL
is stabilized by H bonds with the residues Arg536 (1.73 Å) and
Arg534 (1.67 Å), while the P1 carboxylate has a strong H bond
interaction with nearby Ser547. The rigidity of the F-GUL
linker enables the radiolabel-bearing moiety to remain inside
the pocket. This results in a likely important π–π interaction
with Trp541 and several H bonds with Lys514 (SI Appendix,
Fig. S2A).
Ga-GUL’s longer nine-atom linker chain enables it to enter
deeper, properly occupying the S10 pocket (Fig. 1D), engaging
in H bonds with Lys699 (1.81 Å) and Tyr700 (1.85 Å) through
the P100 acid and Tyr552 (1.70 Å) through the P10 acid. The P1
glutamate carboxylate forms an isosceles triangle interaction
with 2.18 Å distances to both zinc ions. Ga-GUL’s long linker
forms H bonds with Arg511 and a key π-cation interaction with
Lys207 that guides the probe into place (SI Appendix, Fig. S2B).
This structural tour, consistent with the literature (36), gave us
confidence in the binding mode of the probes. Consequently, we
extended this approach to the two NEPC-suspect proteins.
Bakht et al.
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Docking score (kcal/mol)
Receptor
PSMA

NAALADaseL

mGluR8

Ligand

RRD score

IFD score

Cy3-GUL
Ga-GUL
F-GUL
Cy3-GUL
Ga-GUL
F-GUL
Cy3-GUL
Ga-GUL
F-GUL

12.93
11.29
11.66
9.09
1.69
8.20
8.15
4.09
7.67

13.73
13.10
14.83
10.83
12.25
12.91
11.28
6.64
13.16

F-GUL and Ga-GUL Bind NAALADaseL and mGluR8. The GUL moiety in F-GUL binds to NAALADaseL in a manner reminiscent
of the PSMA binding of Ga-GUL, occupying the S10 pocket
due to NAALADaseL’s larger, more open pocket (Fig. 1E and
Movie S3). F-GUL’s P100 glutamate carboxylate forms an H
bond with Arg198, while the P10 carboxylate bridges Zn(1)2+
and Zn(2)2+ at distances of 2.07 and 2.27 Å, respectively. The
aromatic domains of F-GUL are positioned on the outer surface of the receptor, stabilized by a series of H bond interactions with Asn167 and Arg539 (SI Appendix, Fig. S2D). The
carboxylates of Ga-GUL’s glutamates adopt analogous positions
(Fig. 1F and Movie S4), but the linker takes a very different path
out of the active site through the wide channel (SI Appendix, Fig.
S1C); Arg539–P100 carboxylate, Arg455–P10 carboxylate, and
Gly510–ureido carbonyl H bonds hold the linker in conformation.
The Ga-GUL P10 carboxylate interacts with Zn(1)2+ and Zn(2)2+
at distances of 2.17 and 2.09 Å, respectively (SI Appendix,
Fig. S2E). The subtly different structure clearly induces differences in conformation (SI Appendix, Fig. S1C), but docking scores predict both ligands to be excellent partners for
the accommodating NAALADaseL (Table 1).
The mGluRs always self-assemble into homodimers in vivo.
The probes were docked (without restrictions) to each of the
eight mGluR homodimers but showed the best affinity for
mGluR1, mGluR5, and mGluR8 (SI Appendix, Table S3). Curiously, the probes do not interact with the glutamate-binding
active site of these proteins, which is far narrower than either
PSMA’s or NAALADaseL’s; instead, they bind to the large
intermonomer cleft (Fig. 1 G and H and Movies S5 and S6).
Induced-fit docking predicts the best binding to mGluR5 and
mGluR8, with scores on par with NAALADaseL and only
slightly inferior to PSMA (Table 1 and SI Appendix, Table S3).
The docking scores to the other mGluRs were lower (5.2 to
11.5 kcal/mol) but remain favorable. Molecular dynamics simulations helped us understand the high docking score and the
unusual binding mode of the probes with mGluR8, which we
identified as being particularly relevant to NEPC (vide infra).
Very little movement is observed within the binding cleft for
either ligand: most structures fall within a 1 Å cluster adopting
a common conformation (SI Appendix, Fig. S4) due to an extensive hydrogen bonding network that forms between the positively charged residues of the cleft and the negatively charged
probes (SI Appendix, Figs. S5–S16). However, the two probes bind
very differently despite both having strong affinity (SI Appendix,
Fig. S1D), possibly due to the large size of the cleft. F-GUL
(Fig. 1G) is particularly stable, adopting an extended conformation maximizing hydrogen bonding interactions between the
glutamate and the highly positive interprotein region’s residues
Arg188 and Arg240 of one monomer and Ser157, Asn226,
Lys252, Arg255, and Arg268 in the other (SI Appendix, Fig. S2G).
Ga-GUL (Fig. 1H) forms far fewer interactions and instead folds
PNAS j 3 of 11
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Results and Discussion

Table 1. Docking scores for the probes with the target proteins
from both rigid and induced docking models

BIOCHEMISTRY

positive interpretations among patients with a history of radiotherapy (27). Together, the evidence suggests that GUL interacts
fortuitously with other proteins that are up-regulated in cancer
relative to surrounding healthy tissue. Identifying these targets
and determining whether they are indicative of more aggressive
subsets of prostate cancer is a pressing clinical goal.
We hypothesized that PSMA-like proteins such as NAALADaseL and mGluRs, other type II transmembrane peptidases
associated with glutamate signaling, may be responsible for positive results found with GUL-based tracers in NEPC and NE-like
prostate cancer. In this study, we investigated this question with
a cross-disciplinary combination of computational chemistry,
synthesis, molecular biology, and histochemical application of a
GUL-incorporating fluorescent tracer, in vitro Ga-GUL radioligand uptake measurements, mining of clinical data, in vitro overexpression and knockdown of the suspected proteins, and in vivo
patient-derived xenograft (PDX) models.

in on itself, held together by an intramolecular hydrogen bond,
but it still interacts with Ser200, Gln237, and Asn186 of one
monomer and Arg60 and Arg255 in the other. Both complexes
are highly stabilized through these interactions making mGluR8
an exceptional potential molecular target (SI Appendix, Fig. S2H).
These data predict that both F-GUL and Ga-GUL will have
strong affinity, comparable to PSMA, for both NAALADaseL
and a subset of mGluRs. It is conceivable that these two protein classes are responsible for the GUL probes’ efficacy in
detecting PSMA-suppressed cancers; however, it is unknown
whether these proteins are associated with NEPC.

that expression levels of GRM8 rise during the transition to
CRPC and can be significantly elevated in histopathologically
confirmed NEPC (Fig. 3B). Fig. 3C shows the expression of
FOLH1 and GRM8 in the cell lines of the DepMap 21Q3 dataset
(39). We have also determined that the TT cell line expresses
high levels of GRM8 making it a good biochemical positive control (Fig. 3C). In our LTL331 model, progression to NEPC,
LTL331R, leads to higher mGluR8 levels than in the initial
LTL331 AdPC PDX model (Fig. 3 D and E) (39).

Aminopeptidase NAALADaseL Is Elevated in NEPC and NE-Like Prostate Cancer. NAALADaseL, encoded by NAALADL1, has high

gene expression (DGE) analysis in GRM8-high (n = 5) vs. GRM8low tumors (n = 5) in the Stand Up to Cancer/Prostate Cancer
Foundation (SU2C/PCF) Dream Team Dataset 2019 (40). GRM8high tumors suppressed typical AR-signaling markers such as AR,
FOLH1, KLK2/3, and NKX3-1. GRM8-high samples express
higher levels of PCNA, a marker of cell proliferation, and
higher levels of ENO2 (a marker of NEPC) than the GRM8low samples. Kinase enrichment analysis (KEA) results (Fig.
3G) were generated by analyzing the up-regulated and downregulated gene sets using Enrichr (42). A similar KEA on NAALADL1-high samples was performed. Two cyclin-dependent
kinases (CDKs) including CDK1 and CDK2 were the most
enriched kinase in the GRM8-high and NAALADL1-high
cohorts (Fig. 3H). CDK1 and CDK2 both make a complex with
Cyclin A and facilitate cell cycle progression at DNA synthesis
and mitosis. Cyclin A expression is elevated in a variety of
cancers (44), but its significance has not been investigated in
NEPC. Looking at this from a different angle, we observed
this same elevation of Cyclin A1 and CDK1/2 gene expression
among pathologically confirmed NEPC tumors (SI Appendix,
Fig. S21). Transcription changes in cyclin and CDK genes during
progression from AdPC to NEPC in a series of PDX mice
models are illustrated in SI Appendix, Fig. S22A. The nearest
neighbors to FOLH1 analysis in SI Appendix, Fig. S22A shows
Cyclin A1 and E1 and their partners including CDK1 and CDK2
are among the farthest neighbors to FOLH1. Ongoing phase 2
clinical trials for management of CRPC have focused on strategies
using CDK4/6 inhibitors such as palbociclib and abemaciclib (clinical trials identifiers NCT02905318 and NCT04408924). SI
Appendix, Fig. S22A shows Cyclin D1 and CDK4/6 are not correlated with progression to NEPC while the elements of the Cyclin
A1-CDK1/2 complex are differentially expressed in NEPC. The
LNCaP-NE–like cell line also has elevated Cyclin A1 protein levels along with elevated mGluR8 and NAALADL1 (Fig. 3I). The
heat map (Fig. 3J) shows that progression to NEPC is associated
with up-regulation of CDK1/2, CCNA1, GRM8, and NAALADL1. As a preliminary exploration of the role of CDK1/2
activity in the proliferation of NEPC, our LNCaP models were
treated with dinaciclib, a potent inhibitor of CDKs 1, 2, 5, and 9
(44). An enzalutamide (ENZ)-resistant LNCaP-NE–like cell line
with an elevated level of Cyclin A1 showed a lower half-maximal
inhibitory concentration (IC50) than the ENZ-sensitive
LNCaP–wild type (WT) (Fig. 3K). The identified sensitivity of
NE-like LNCaP supports the feasibility of dinaciclib as an inhibitor of CDK1/2 for NEPC management; this result is worthy of
future exploration. Likewise, CCNA1, CDK1/2, PCNA, NAALADL1, and GRM8 expression are elevated in pathologically
confirmed NEPC (Fig. 3L and SI Appendix, Figs. S23 and S24).
Collectively, these data show that the mGluRs and NAALADaseL are clearly associated with the NEPC gene signature and
correlate positively with Cyclin A1 and CDK1/2 expression.
These data alone do not dissect causality, and it is possible that
elevated expression of mGluR, NAALADaseL and Cyclin A1,
CDK1/2 in NEPC are part of separate underlying mechanisms.
However, these data are intriguing, and these molecular relationships deserve further investigation.

sequence similarity to PSMA (SI Appendix, Fig. S3) (37). They
share more than 90% structurally equivalent residues, with
near-complete identity at the active site (SI Appendix, Fig. S3;
PDB ID 2XEJ and 4TWE) (38). We examined the expression of
NAALADaseL using the LTL331 PDX model of prostate cancer progression from adenocarcinoma to NEPC (Fig. 2A) (41).
NAALADL1 gene expression remains minimal during the effective treatment period but spikes as the tumor becomes resistant to
therapy, and peak expression occurs when the tumor transitions
to NEPC. This profile inversely correlates with that of FOLH1
(Fig. 2A). We examined the relative expression of FOLH1 and
NAALADL1 in the well-established cells lines of the DepMap
21Q3 dataset (n = 1,377) (39). NAALADL1 gene expression is
low in typical prostate cancer cell lines, while it is high in the
human medullary thyroid carcinoma TT cell line (Fig. 2B). At
the protein level, our preprogression LTL331 model is PSMApositive and NAALADaseL-negative, while after progressing
to a PSMA-negative NEPC form, we observe low, but detectable,
NAALADaseL positivity (Fig. 2 C and D). The RNA-seq analysis
of metastatic prostate cancer tumors also shows that NAALADL1
expression rises during the transition to castration-resistant prostate cancer (CRPC) and can be significantly elevated in histopathologically confirmed NEPC (Fig. 2E). This trend is mirrored
in the Dream Team patient dataset (Fig. 2F) (40). When ordering
patients by increasing AR score, NAALADL1 expression is lower,
while PSMA expression (FOLH1) is higher; furthermore, NEPC
score is strongly positively correlated with NAALADL1 expression. As NAALADL1 is elevated in low-PSMA prostate cancers
with an NE-like gene signature (Fig. 2 G and H), these data are
consistent with the computational supposition that NAALADaseL may be one target of the GUL probes on PSMAsuppressed cells.
mGluRs Are Up-Regulated during Progression to NEPC. The second
class of proteins identified for investigation was the mGluRs,
encoded by GRMs. While increased expression of mGluR2 has
already been reported in PSMA-positive cancers (14), we
observed a significant up-regulation in the expression of most
mGluR family members during cancer progression from prostate
adenocarcinoma (AdPC) to NEPC in our PDX mouse model
(SI Appendix, Fig. S17) and in the NCIH660 cell line model of
NEPC (Fig. 3A). Following castration, GRM2, GRM3, GRM4,
and GRM8 all become increasingly expressed as FOLH1 expression down-regulates (SI Appendix, Fig. S17). Furthermore, their
expression is strongly positively correlated to that of SRRM4, the
archetypal biomarker of NEPC (SI Appendix, Fig. S18). Data
mining the Memorial Sloan Kettering Cancer Center cohort (43)
for prostate tumor survival identifies that high levels of GRM1,
GRM3, GRM4, and especially GRM5 and GRM8, are correlated
with shorter times to biochemical recurrence, with GRM8 showing the most significant effect (SI Appendix, Fig. S19). Further
investigation revealed that high levels of GRM8 expression are
associated with a higher prevalence of metastatic cancer and
higher Gleason scores (SI Appendix, Fig. S20). Our data indicate
4 of 11 j PNAS
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Cyclin A1-CDK1/2 Activity in NEPC Is Associated with NAALADaseL
and mGluR8 Expression. Fig. 3F shows a volcano plot of differential
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A

B

AdPC = adenocarcinoma, CRPC = castration-resistant prostate cancer

Treatment

PSMA-positive prostate cell line
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Fig. 2. Differential expression of NAALADL1 in NEPC and NE-like PC as an alternative target for GUL ligands. (A) Schematic of our established PDX mice
models of adenocarcinoma (AdPC) and NEPC and alteration of FOLH1 and NAALADL1 gene expression during the transition from AdPC to NEPC. (B) The
expression of FOLH1 and NAALADL1 in well-established cells lines (n = 1,377) of DepMap 21Q3 dataset (39). (C) PSMA and NAALADaseL levels in LTL331
and LTL331R models were detected by immunoblotting. TT and 22Rv1 cell lines were used as NAALADaseL- and PSMA-positive control samples, respectively. (D) Tissue sections of LTL331 models stained with nuclear fast red to visualize cell nuclei and blue chromogenic substrate used for detection of
PSMA and NAALADaseL. (E) NAALADL1 gene expression level in different cohorts of metastatic prostate cancer samples. The expression levels are normalized to the mean of entire samples in the cohort (n = 155). (F) Evaluation of the expression of FOLH1 and NAALADL1 genes and their association with AR
and NEPC scores in the SU2C/PCF Dream Team Dataset 2019 (40). The high levels of NAALADL1 gene expression in AdPC are associated with both lower
levels of FOLH1 gene expression and higher levels of ENO2 gene expression, the archetypal NE marker. (G) Pearson’s correlation between FOLH1 (blue)
and NAALADL1 (red) expression levels. (H) Pearson’s correlation between ENO2 (blue) and NAALADL1 (red) expression levels among AdPC samples (n =
199) generated by R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl).
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Fig. 3. Differential expression of GRM genes is associated with higher expression of NEPC markers and Cyclin A1, CDK1, and CDK2. (A) The heat map
plot of the expression levels of GRMs levels in well-established prostate cell lines. (B) Waterfall plot of RNA-seq mGluR8 gene expression levels in different
cohorts of prostate samples (*P < 0.001, Wilcoxon rank sum test). (C) The expression of FOLH1 and GRM8 in well-established cells lines (n = 1,377) of the
DepMap 21Q3 dataset (39). (D) mGluR levels in LTL331 cell models were detected by immunoblotting. TT and LNCaP cell lines were used as mGluR8 positive and negative control samples, respectively. (E) Tissue sections of LTL331 models stained with nuclear fast red to visualize cell nuclei and blue chromogenic substrate used for detection of mGluR8. (F) A volcano plot of DGE analysis in GRM8-high (n = 5) vs. GRM8-low tumors (n = 5) in the SU2C/PCF
Dream Team Dataset 2019 (40). The red points represent up-regulated differentially expressed genes, the blue points represent down-regulated differentially expressed genes, and the black points represent nondifferentially expressed genes. (G) Bar plot for the log10 of the P value of KEA in GRM8-high vs.
GRM8-low tumors generated by the Enrichr tool (42). (H) Venn diagram illustrating the intersections between KEA data of GRM8-high and NAALADL1high tumors. (I) Cyclin A1, PSMA, mGluR8, and NAALADaseL levels in LNCaP models were detected by immunoblotting. (J) Heat map plot of expression
levels of GRM8, NAALADL1, CCNA1, and CDK1 and their association with AR markers and NE markers in in PDX models. (K) Growth inhibition curves and
IC50 of ENZ-sensitive LNCaP-WT and ENZ-resistant LNCaP-NE–like cell lines treated with CDK1/2 inhibitor (dinaciclib). (L) A plot of gene expression analysis
in NEPC (n = 22) vs. CRPC (n = 31). P value threshold = 0.05.
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Cy3-GUL Binds to PSMA In Vivo. Flow cytometry demonstrates far
stronger uptake of Cy3-GUL into PSMA-positive LNCaP cells
relative to PSMA-negative DU145 cells (SI Appendix, Fig. S26 A
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GUL Probes Are Selectively Taken Up by mGLuR and NAALADaseL.

To investigate the affinity of GUL-based probes for mGluR8, we
measured the uptake of Cy3-GUL into PSMA-negative DU145
cells both with and without overexpression of mGluR8 (Fig. 5
A–C). LNCaP-PSMA–positive cells were used as a positive control. The Cy3-GUL signal is predominantly localized to the cytoplasm. This is consistent with GUL-tracer localization; they are
found both bound to PSMA at the membrane and internalized
to the cytoplasm in a time-dependent fashion (45). Immunofluorescence microscopy demonstrates a fivefold increase in Cy3GUL uptake when mGLuR8 was overexpressed (Fig. 5C). The
involvement of mGluR8 is further supported by its up-regulation
when PSMA-negative DU145 cells are driven to develop NE features by epidermal growth factor (EGF) and dibutyryl cAMP
cotreatment and simultaneous serum starvation as previously
described (Fig. 5D and SI Appendix, Fig. S28 A and B) (46). After
treatment, cells display neuronal/neuroendocrine characteristics
including neurite-like outgrowth (SI Appendix, Fig. S28C), while
increasing their expression of select mGluR genes (including
GRM4 and GRM8) (SI Appendix, Fig. S28C). Similarly, differential
expression of GRMs was observed following overexpression of
SRRM4 as a regulator of NEPC (SI Appendix, Fig. S29). Although
not expressing PSMA, these cells still significantly increase their
uptake of Cy3-GUL (Fig. 5E), supporting our hypothesis that
GUL radiolabels may bind mGluRs such as mGluR8 and that
these mGluRs could be markers of NEPC emergence.
To determine whether NAALADaseL can bind Cy3-GUL, we
performed a knockdown of NAALADL1 in WT LNCaP cells and
LNCaP cells driven to a neuroendocrine phenotype (LNCaPNE-like) after treatment with charcoal-stripped serum as previously described (17) (SI Appendix, Fig. S30 and Fig. 5 F and G).
PCR analysis both confirmed the successful NAALADL1 knockdown and demonstrated that NAALADL1 gene expression is significantly higher in the LNCaP-NE-like line over control (Fig.
5F). When treated with the probe, Cy3-GUL uptake positively
correlated with NAALADaseL levels. Cy3-GUL uptake was significantly reduced in LNCaP-NE cells with NAALADL1 knockdown; however, probe uptake was unchanged in WT LNCaP
cells despite successful knockdown (Fig. 5G). This is likely due
to high PSMA expression in LNCaP control cells which was
unaffected by NAALADL1 knockdown (Fig. 5 G and H). To
provide additional support that these effects were not due to
some odd interaction with the dye rather than GUL, we further measured 68Ga-PSMA-11 uptake in a variety of cell lines
with different levels of PSMA, mGluR, and NAALADaseL.
Fig. 5I shows Western blot analyses of PSMA levels in LNCaP
and TT cell lines. For small interfering RNA (siRNA)-mediated GRM8 and NAALADL1 knockdown in TT cells, cells were
transfected with either NAALADL1 Smart Pool and/or GRM8
Smart Pool or a nontargeting control siRNA (SI Appendix, Fig.
PNAS j 7 of 11
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GUL probes may interact well with mGluRs, especially mGluR8,
and NAALADaseL, explaining their binding to PSMA-suppressed
cells. To investigate this possibility histochemically we needed a
fluorescent version of the GUL probe. To this end, we analyzed
our predicted binding modes of F-GUL and Ga-GUL to design
a cyanine dye-incorporating fluorescent probe (Cy3-GUL;
SI Appendix, Fig. S25) analog of the clinical radiolabels (Fig. 4).
A series of related probes with different linkers were computationally screened using induced-fit docking algorithms, but the best
binding results were observed for a synthetically straightforward
analog, Cy3-GUL, where a five-atom linker connects the GUL
pharmacophore to the cyanine. This is a far closer connection than
employed in either of the radiolabels but maintains the steric bulk
at approximately the same distance from the GUL pharmacophore
as F-GUL’s naphthylalanine.
Comparing the predicted binding of Cy3-GUL with PSMA to
that of Ga-GUL and F-GUL suggests that Cy3-GUL will adopt
a similar pose to F-GUL, interacting with one of the Zn2+ ions
through the P100 carboxylate (Fig. 4A and Movie S7). Cy3-GUL
forms fewer and less consistent hydrogen bonding interactions
than the other probes, and like F-GUL (but unlike Ga-GUL), it
does not enter the S10 pocket; it also lacks F-GUL’s imaging
moiety, preventing the formation of a series of key interactions
(SI Appendix, Fig. S2C). However, it does hydrogen bond to
Arg534, Ser547, Tyr552, and Tyr700. As a result, greater rootmean-square deviation (RMSD) fluctuations occur for Cy3GUL during the molecular dynamics (MD) simulation (SI
Appendix, Fig. S4). Although more flexible, Cy3-GUL still forms
enough key interactions to remain an excellent ligand for PSMA.
Cy3-GUL is predicted to bind very well to NAALADaseL with
similar affinity as F-GUL and Ga-GUL (Fig. 4C and Table 1).
The binding modes of all three probes are different due to the
greater size of the NAALADaseL active site; however, they all
bind with the GUL moiety extended into the binding pocket
(Fig. 4D and Movie S8). In the case of Cy3-GUL, the P100 carboxylate forms interactions with one of the Zn2+ ions (bound to P1
in Ga-GUL and P10 in F-GUL). Several strong hydrogen bonds
and salt bridges are formed with the receptor (Arg198, Arg539,
Tyr544, and Gly195 backbone NH) which stabilize the complex
and remain intact throughout the MD simulation. These are similar to those observed for F-GUL; however, F-GUL forms several
additional interactions. Arg198 and Tyr544 are particularly
important and form key interactions with all three probes (SI
Appendix, Fig. S2F). Cy3-GUL again shows slightly greater fluctuation in the RMSD, largely due to the flexibility in the dye and
linker domains due to their less charged nature.
Cy3-GUL shows stronger affinity for mGluR8 than for any of
the other mGluRs (Fig. 4E, Table 1, and SI Appendix, Table S3),
adopting a bound conformation distinct from that of the other
two probes (Fig. 4F and Movie S9) with the GUL moiety buried
deep within the highly charged cleft (Fig. 4E). Three extremely
stable salt bridges are formed between the P1, P10 , and P100 carboxylates and the Arg255, Arg188, and Arg255 of the second
subunit (SI Appendix, Fig. S2I). Due to these key interactions,
minimal RMSD fluctuations are observed in the MD simulation
of the Cy3-GUL–mGluR8 complex. With both sufficient predicted binding and close agreement in the binding mode of the
GUL pharmacophore to those of the clinical radiolabels, this
probe was thus synthesized for in vitro evaluation, which we
accomplished from a protected GUL moiety and our previously
prepared cyanine dye (SI Appendix, Fig. S25 and accompanying
discussion) (20).

and B). This indicates that although Cy3-GUL is predicted to
bind well to three different proteins, it is not generally promiscuous: it requires PSMA to bind the cell—both DU145 and
LNCaP have low endogenous expression levels of both mGluRs
and NAALADaseL (SI Appendix, Fig. S26E). In addition, the
PSMA-positive LNCaP cells do not become fluorescent when
they are exposed to the unconjugated dye, indicating the GUL
moiety is essential for selective uptake (SI Appendix, Fig. S26D).
Similarly, PSMA-negative DU145 cells, an AdPC cell line, show
almost no Cy3-GUL uptake (SI Appendix, Fig. S26 C and D).
Functionally, Cy3-GUL exposure shows no cytotoxicity to
LNCaP or DU145 cells at any tested dose regardless of cell type
(SI Appendix, Fig. S27). These data, along with the computational modeling, suggest that Cy3-GUL is an acceptable fluorescent homolog of the two clinically deployed PET reagents; we
consequently used it to validate our hypothesis that GUL probes
bind mGluR8 and NAALADaseL.
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A Synthetic Fluorescent Cy3-GUL Probe Is Predicted to Bind to All Three
Proteins. The biochemical and computational data suggest that the
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Fig. 4. Cy3-GUL probe binds to the PSMA and NAALADaseL active sites and mGluR8 cleft similar to the clinical radiopharmaceuticals. (A) Computed conformation of Cy3-GUL within the PSMA active site (2XEG). (B) Comparison of Cy3-GUL (GUL moiety in deep blue, dye in cyan), Ga-GUL (GUL moiety in maroon, ligand
in red), and F-GUL (GUL moiety in purple, pseudopeptide in peach) within the PSMA active site. (C) Cy3-GUL’s computed conformation within the NAALADaseL
active site (4TWE). (D) Comparison of Cy3-GUL, Ga-GUL, and F-GUL in the NAALADaseL active site. Coloring is the same as in B. (E) Computed conformation of
Cy3-GUL within the mGluR8 cleft (6BSZ). (F) Comparison of Cy3-GUL, Ga-GUL, and F-GUL in the mGluR8 cleft. Coloring is the same as in B.

S31). Normalized 68Ga-PSMA-11 uptake in LNCaP and TT cell
lines following inhibition of PSMA, mGluR8, and NAALADaseL is represented in Fig. 5J. As expected, 68Ga-PSMA-11
uptake in LNCaP falls drastically upon PSMA inhibition.
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However, our known PSMA-negative TT cells have higher
uptake of 68Ga-PSMA-11 which implies the affinity of 68GaPSMA-11 to PSMA-like proteins. Importantly, siRNAmediated knockdown of both GRM8 and NAALADL1 in TT
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Fig. 5. NAALADaseL and mGluR8 regulate uptake of GUL-based tracers. The overexpression of mGluR8 in a PSMA-negative cell line induces uptake of Cy3-GUL.
(A) Representative immunocytochemistry images of cells stained with Hoechst (blue), Cy3-GUL (green), and actin (red). (Scale bar, 20 μm.) (B) Western blot analyses of PSMA and mGluR8 protein levels. (C) Quantiﬁcation of Cy3-GUL uptake, analyzed by one-way ANOVA. (D) NE transdifferentiation of DU145 cell line by
EGF/cAMP treatment and serum starvation increases Cy3-GUL uptake. DU145 cell line was treated with cAMP (0.25 mM), EGF (50 ng/mL), and gradient levels of
fetal bovine serum (FBS), while the control group (F10NN model) was treated with 10% FBS. Then after 3 d, the cells were incubated with 100 nM Cy3-GUL for 1 h
and analyzed by PCR and immunocytochemistry. (E) Representative immunocytochemistry images of cells stained with Hoechst (blue), Cy3-GUL (green), and actin
(red). The NAALADL1 gene is up-regulated in the NE-like cell line model, and its inhibition could suppress GUL ligand uptake. (Scale bar, 20 μm.) (F) Quantiﬁcation of
NAALADL1 gene expression using real-time PCR. (G) Quantiﬁcation of Cy3-GUL uptake following inhibition of NAALADL1 gene by ﬂow cytometry. (H) Representative images of Cy3-GUL uptake in AdPC and NE-like models of LNCaP cell lines following inhibition of NAALADL1 gene using siRNA technology. (Scale bar, 20 μm.)
(I) Western blot analyses of PSMA levels in LNCaP and TT cells lines. (J) Normalized 68Ga-PSMA-11 uptake in LNCaP and TT cell lines following inhibition of PSMA,
mGluR8, and NAALADaseL. Cell uptake was expressed as counts per minute per milligram (cpm/mg) of total proteins. *P < 0.05, **P < 0.01 and ***P < 0.001.
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cells leads to suppression of 68Ga-PSMA-11 nonspecific
uptake. These two proteins appear to be excellent candidates
for the non-PSMA binding of these GUL probes, and these
experiments are also very much in line with the fluorescence dye
data and the computational predictions. Cy3-GUL can be used in
preclinical in vitro experiments as a nonradioactive PSMA tracer
which demonstrates full binding capabilities of the GUL-based
probes including the binding to PSMA-like proteins.
Conclusion
GUL-based probes are the state-of-the-art selective PSMAtargeting diagnostic tools, but emerging data show that they
also bind to PSMA-negative prostate cancer tissues. Fortunately, these unknown target proteins do appear to be associated with prostate cancer, supporting that GUL-based probes
function as multitargeting probes and are a benefit over
approaches depending on antibody labels. The identities of
these proteins were previously unknown and are of interest. As
cells develop neuroendocrine features, both the GRMs and
NAALADL genes are up-regulated while the gene encoding
PSMA, FOLH1, levels fall. Our computational modeling suggested that the GUL probes should bind to the encoded proteins, consequently resulting in GUL probe recognition of
PSMA-negative metastatic NEPC lesions. Fluorescent analog
Cy3-GUL binds to these proteins, validating them as binding
targets of GUL. Uptake of this and known radiochemical GUL
probes depends on the presence of these proteins.
As important as the identification of these protein targets is,
this project highlights the benefits of integrating computational
and synthetic chemistry, with data mining of clinical databases
and conducting in vitro and in vivo experiments to accelerate the
validation of protein targets. This work explains why caution must
be taken on clinical conclusions regarding treatment decisions
made with PSMA-targeted imaging alone and suggests that
mGluR and NAALADaseL may represent targets for imaging
and therapeutic purposes. Paired probes may be useful for early
detection of cancer progression to help inform treatment decisions. These proteins may play a role in NEPC, and their biochemical importance to this cancer deserves greater attention.
National Comprehensive Cancer Network (NCCN) Clinical
Practice Guidelines in Oncology (NCCN Guidelines) currently
recommend consideration of platinum-based chemotherapy
regimens for NEPC. There is no known successful next line
therapy for NEPC patients, particularly after platinum-based
chemotherapy (47). AR independence and PSMA-negativity of
NEPC have been a rationale for exclusion of PSMA-targeted
therapy for NEPC tumors. In this work, we show GUL-targeted
PET ligand can be used for imaging of PSMA-negative prostate
cancers such as NEPC. This work supports the potential that
PSMA-directed radiopharmaceuticals may also then target
subsets of NEPC tumors with elevation of PSMA-like proteins
mGluR8 and NAALADaseL. This would then make NEPC
patients good candidates for some of the emerging PSMAtargeted clinical trials.
The mainstream clinical trials using CDK inhibitors for management of CRPC are focused predominantly on CDK4/6 inhibitors like palbociclib (48). This work shows that Cyclin D1 and
CDK4/6 are not elevated with progression to NEPC; however,
Cyclin A1 and partnering kinases CDK1/2 are significantly overexpressed in NEPC. We provide early evidence that NEPC shows
sensitivity to the CDK1/2 specific inhibitor dinaciclib. This provides the exciting possibility that this could be a treatment avenue
for the management of NEPC.
Methods
Cell Culture. All cell lines were purchased from the American Type Culture Collection (ATCC). SI Appendix includes the details of the culturing conditions.
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https://doi.org/10.1073/pnas.2025710119

The LNCaP-NE–like cell line was derived by culturing LNCaP cells in RPMI1640
medium with 10% charcoal-stripped as previously characterized (20). LNCaP
cells were treated with ENZ or dinaciclib (SCH727965) from Selleckchem.
Plasmids and Knockdown Experiments. GRM8-Tango was a gift from Dr. Bryan
Roth (University of North Carolina, Chapel Hill, NC) (Addgene plasmid no.
66393) (49). For siRNA-mediated knockdown experiments, TT cells were transfected with Dharmacon Smart Pool according to the manufacturer's protocol.
The listed siRNAs in SI Appendix, Table S1 were used for knockdown experiments of LNCaP cells. Transfections were performed using Lipofectamine 3000
(Life Technologies). Additional details of the experiments are provided in
SI Appendix.
Immunoblotting, Immunocytochemistry, and Immunohistochemistry. SI Appendix
includes a list of used antibodies. Immunoblotting and immunocytochemistry techniques were described previously (20). For immunohistochemistry,
slide-mounted tissue sections were deparafﬁnized and developed in a fashion
similar to that previously described (50) except that blue chromogenic substrate and nuclear fast red counterstain (Vector Laboratories) were used following diluted biotinylated secondary antibody (Jackson Immunoresearch Laboratories) and phosphatase avidin D (Vector Laboratories) incubation steps.
Cytotoxicity Evaluation and Cytometric Analysis. Cell viability was measured
by methyl thiazolyl tetrazolium assay of Sigma-Aldrich according to the manufacturer's protocol. Cytometric analysis was performed using a BD LSRFortessa
X-20 Flow Cytometer System.
Synthesis of Cy3-GUL and In Vitro Imaging. The chemical synthesis of a cyanine dye-incorporating ﬂuorescent probe (Cy3-GUL) is summarized in
SI Appendix, Fig. S25. SI Appendix includes synthetic chemistry experimental
details. For the synthesis of the dye intermediates in SI Appendix, Fig. S25,
please see our previous publication (20). For in vitro imaging, cells were
seeded in 12-well dishes (Corning) overnight. Cells were treated with 100 nM
Cy3-GUL and 100 ng/mL Hoechst 33342 (Thermo Scientiﬁc) for 5, 10, 30, 60,
and 120 min. Cells were washed with phosphate buffered saline (PBS) and
prepared for live imaging. SI Appendix contains additional imaging condition.
In Vitro 68Ga-Labeled PSMA-11 Uptake Assay. As previously described (6), 48 h
prior to the assay, cells were seeded in the 24-well plate. 68Ga-labeled PSMA-11
(37 KBq) was added to each well. After 45 min incubation at 37 °C, cells were
washed with ice-cold PBS, trypsinized and solutions were then collected for
analysis by a gamma counter (Wizard2; PerkinElmer). SI Appendix includes
additional experimental details.
Data Mining and Gene Expression Analysis. DGE and KEA analyses were performed using BioJupies (51) and Enrichr (42) platforms. Kaplan–Meier plots
and heat maps were generated using camcAPP (52), Broad Institute Morpheus
software and R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl).
SI Appendix includes additional information about statistical analysis.
Computational Analyses. Docking was performed using the Glide (53) module
€ dinger suite. The MD simulations of the ligands were performed
of the Schro
using Amber16 to study protein–ligand interactions and complex stability.
SI Appendix includes additional information about MD protocol and preparation of protein and ligands.
PDX Models. We previously characterized and validated our PDX models as
having AdPC and NEPC mRNA and protein signatures (41). The Institutional
Review Board and Animal Care Committee of the University of British Columbia approved this study, and all subjects signed a written informed consent.
Data Availability. Data associated with the reported ﬁndings are available
in the manuscript or supplementary information. Samples of the ﬂuorescent
Cy3-GUL probe are available on request while current supplies last for collaborative research purposes (contact J.F.T.).
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